Elesclomol (STA-4783)

Catalog No.S1052

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016.. Elesclomol (STA-4783) purchased from Selleck.

    BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Targets
HSP70 [1]
(Cell-free assay)
In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml\TTY5pcWKrdHnvckBw\iCqdX3hckBPV1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEA{NjZ4ZT2wOUDPxE1? NIm0b2lUSU6JRWK=
CAL-51 cell NFrjfWdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4TTN2lvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOjZibl2= NFPJeo1USU6JRWK=
ABC-1 cell NGTrSoFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlTlTY5pcWKrdHnvckBw\iCqdX3hckBCSkNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|Y2KG6P MmP3V2FPT0WU
A2780 cell M4Xu[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYLJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61PVQhdk1? MkDqV2FPT0WU
ES1 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1HVO2lvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63OFkhdk1? NEHNWIZUSU6JRWK=
HUTU-80 cell M{\NeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWnJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc6OSCwTR?= Mnq0V2FPT0WU
NCI-H292 cell M3HWV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUPJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45QDZibl2= NGntd|hUSU6JRWK=
NB69 cell M2rtVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGTKV4NKdmirYnn0bY9vKG:oIHj1cYFvKE6ENkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlIzKG6P NX;HdpFiW0GQR1XS
ES8 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXrJcohq[mm2aX;uJI9nKGi3bXHuJGVUQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwM{Kgcm0> NXnQc3JIW0GQR1XS
BCPAP cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUfJcohq[mm2aX;uJI9nKGi3bXHuJGJEWEGSIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6zOEBvVQ>? NV3yXIpCW0GQR1XS
T-24 cell NEn6Vo1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFjmTXJKdmirYnn0bY9vKG:oIHj1cYFvKFRvMkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU2KG6P NV3ac5dXW0GQR1XS
EW-16 cell NH7MVYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWHJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NUBvVQ>? NHPHcINUSU6JRWK=
OVCAR-5 cell NInic|RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYXqRVhSUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk02KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS56MzDuUS=> NFTmPWdUSU6JRWK=
SF126 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUGzU3RzUW6qaXLpeIlwdiCxZjDoeY1idiCVRkGyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQTVibl2= MXPTRW5ITVJ?
KP-4 cell NFLIVlVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4TROmlvcGmkaYTpc44hd2ZiaIXtZY4hU1BvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNVchdk1? MnmyV2FPT0WU
GAMG cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mon0TY5pcWKrdHnvckBw\iCqdX3hckBISU2JIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj61NUBvVQ>? MoL3V2FPT0WU
HOS cell M4nKS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEfH[HdKdmirYnn0bY9vKG:oIHj1cYFvKEiRUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOVMhdk1? Moj5V2FPT0WU
CHL-1 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{T6bmlvcGmkaYTpc44hd2ZiaIXtZY4hS0iOLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlgyKG6P M1q5c3NCVkeHUh?=
AGS cell M3W1S2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUfJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwOE[gcm0> NVW4fmt{W0GQR1XS
MDA-MB-157 cell M{f4VWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVnJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xOVch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjl{IH7N NUjJcY05W0GQR1XS
HSC-3 cell MnvXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUPPVFRTUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODJibl2= MknOV2FPT0WU
CAL-72 cell MlrnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NELhN5FKdmirYnn0bY9vKG:oIHj1cYFvKEODTD23NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODJibl2= NVXWOpROW0GQR1XS
NBsusSR cell M3HkNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIDnOJlKdmirYnn0bY9vKG:oIHj1cYFvKE6Ec4XzV3Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjF|IH7N NX[2SWNGW0GQR1XS
ES7 cell NI\sVYtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmjtTY5pcWKrdHnvckBw\iCqdX3hckBGWzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkW5JI5O NFLFNIlUSU6JRWK=
H-EMC-SS cell M2rn[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2PndmlvcGmkaYTpc44hd2ZiaIXtZY4hUC2HTVOtV3Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ6IH7N MlzXV2FPT0WU
NCI-H1703 cell NFP6TlFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{DVdmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO|A{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy54ODDuUS=> NEDBXXhUSU6JRWK=
BHT-101 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NETpOWNKdmirYnn0bY9vKG:oIHj1cYFvKEKKVD2xNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njd{IH7N MWnTRW5ITVJ?
SK-OV-3 cell NFHxPIJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXS0dnpDUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy55NTDuUS=> M2PVU3NCVkeHUh?=
EW-24 cell NHTjXY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlzOTY5pcWKrdHnvckBw\iCqdX3hckBGXy1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPFMhdk1? M3PyUnNCVkeHUh?=
PSN1 cell M{PJ[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVPJcohq[mm2aX;uJI9nKGi3bXHuJHBUVjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lki0JI5O NGXVXopUSU6JRWK=
OVCAR-8 cell NGDFUVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYPIPHFJUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk05KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy57OTDuUS=> M4G3fXNCVkeHUh?=
NCI-H1563 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFj1WlRKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVU3OyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwMUOgcm0> MX7TRW5ITVJ?
SW756 cell Mlv5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYLJcohq[mm2aX;uJI9nKGi3bXHuJHNYPzV4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6xN{BvVQ>? M2fZe3NCVkeHUh?=
A375 cell Mom0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn\qTY5pcWKrdHnvckBw\iCqdX3hckBCOzd3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6xOEBvVQ>? M{\sZXNCVkeHUh?=
Ca9-22 cell M3;LWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUHjeWVxUW6qaXLpeIlwdiCxZjDoeY1idiCFYUmtNlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjJ3IH7N MVvTRW5ITVJ?
SW1990 cell M2G5N2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGDVcIlKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUm5NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOzJibl2= M3LwR3NCVkeHUh?=
ES4 cell NHXvXFhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3PUVmlvcGmkaYTpc44hd2ZiaIXtZY4hTVN2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6zPUBvVQ>? NXTaUXBHW0GQR1XS
HCE-T cell Mn\0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIGyWY5KdmirYnn0bY9vKG:oIHj1cYFvKEiFRT3UJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE41PSCwTR?= Mm\YV2FPT0WU
MOLT-16 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NILvbmpKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjV|IH7N NELKNW5USU6JRWK=
HSC-4 cell NWnqNoJVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnjRTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuPEBvVQ>? NF6yTVVUSU6JRWK=
NCI-SNU-1 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXTkT2JjUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtV25WNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lki2JI5O M2jUdXNCVkeHUh?=
EW-11 cell NI\kfHlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3u5cWlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlkhdk1? M1G3eXNCVkeHUh?=
HT-1080 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGTReFJKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl7IH7N Ml7VV2FPT0WU
MES-SA/Dx5 cells NIPkWXZEgXSxdH;4bYNqfHliYYPzZZk> NGXCPYFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTVNvU1GvSJg2KGOnbHzzMEBKSzVyPUWgcm0> NV70c3J1OjN7M{e5PFE>
SW1710 cell MnjiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkHDTY5pcWKrdHnvckBw\iCqdX3hckBUXzF5MUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlE3KG6P M33CenNCVkeHUh?=
EW-1 cell NX75cJZYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1PXfGlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuNlQhdk1? MY\TRW5ITVJ?
BV-173 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkTsTY5pcWKrdHnvckBw\iCqdX3hckBDXi1zN{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM6KG6P MWXTRW5ITVJ?
TE-8 cell M1Hlcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4TiXmlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFEhdk1? MWPTRW5ITVJ?
G-401 cell NW\vZlBMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVjwcZlmUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDNibl2= NHvBT|RUSU6JRWK=
KOSC-2 cell NHHVPWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MljxTY5pcWKrdHnvckBw\iCqdX3hckBMV1OFLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ2KG6P NWj5VWJSW0GQR1XS
HuCCT1 cell MoLuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWPJcohq[mm2aX;uJI9nKGi3bXHuJGh2S0OWMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOVIhdk1? M3rmWnNCVkeHUh?=
FADU cell M2fUcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWfYbVNXUW6qaXLpeIlwdiCxZjDoeY1idiCIQVTVJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43PiCwTR?= M{nRRXNCVkeHUh?=
MHH-ES-1 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml\qTY5pcWKrdHnvckBw\iCqdX3hckBOUEhvRWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPjlibl2= MnvkV2FPT0WU
ES3 cell NEXJUm9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEP1TZBKdmirYnn0bY9vKG:oIHj1cYFvKEWVMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|khdk1? M2XqcXNCVkeHUh?=
OVCAR-4 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXTJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlg4KG6P MoXkV2FPT0WU
HD-MY-Z cell NGPFWGVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmP3TY5pcWKrdHnvckBw\iCqdX3hckBJTC2PWT3aJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46OSCwTR?= M{LjWnNCVkeHUh?=
human JAR cell Ml65S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIKxTlJKdmirYnn0bY9vKG:oIHj1cYFvKEqDUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuPVchdk1? M3XV[XNCVkeHUh?=
A427 cell M3ziUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mo\lTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj6wO{BvVQ>? MYXTRW5ITVJ?
697 cell M1q0bGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF76SWhKdmirYnn0bY9vKG:oIHj1cYFvKDZ7NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uNVMhdk1? M2rw[HNCVkeHUh?=
OVCAR-3 cell NVfUZoFbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVzJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlIhdk1? NUjIcGFvW0GQR1XS
human NB14 cell M4nkNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkLhTY5pcWKrdHnvckBw\iCqdX3hckBPSjF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj62OEBvVQ>? MYrTRW5ITVJ?
GB-1 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkfWTY5pcWKrdHnvckBw\iCqdX3hckBISi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj63NUBvVQ>? MmfYV2FPT0WU
COR-L105 cell Mk\lS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkXZTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEGwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPzZibl2= NY\a[5d7W0GQR1XS
647-V cell NHPJOIFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIHqblZKdmirYnn0bY9vKG:oIHj1cYFvKDZ2Nz3WJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok46KG6P MUDTRW5ITVJ?
human K5 cell M4rySGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlriTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdibl2= M2DMWXNCVkeHUh?=
DMS-273 cell MlL0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV:yZ|NXUW6qaXLpeIlwdiCxZjDoeY1idiCGTWOtNlc{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yNjDuUS=> MXHTRW5ITVJ?
UM-UC-3 cell M1\zXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUXJcohq[mm2aX;uJI9nKGi3bXHuJHVONVWFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlA3KG6P NIjTZnlUSU6JRWK=
HEL cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml\CTY5pcWKrdHnvckBw\iCqdX3hckBJTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15LkC4JI5O NH\DcnlUSU6JRWK=
human KU-19-19 cell M1LFWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHzhfVZKdmirYnn0bY9vKG:oIHj1cYFvKEuXLUG5MVE6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yOTDuUS=> NWf1OIRSW0GQR1XS
MC-IXC cell NInlSpNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NU[0cHhoUW6qaXLpeIlwdiCxZjDoeY1idiCPQz3JXGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjF5IH7N MkHHV2FPT0WU
human H4 cell NYXPb5U1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVH5VZZsUW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuNlUhdk1? M1HvPXNCVkeHUh?=
NUGC-3 cell NH7tUVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlK4TY5pcWKrdHnvckBw\iCqdX3hckBPXUeFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlM{KG6P MWrTRW5ITVJ?
CHP-212 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1zLdWlvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOzRibl2= M3rDeHNCVkeHUh?=
human SW982 cell Mn\1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWDJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz60OEBvVQ>? M2\XeXNCVkeHUh?=
C-33-A cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M333S2lvcGmkaYTpc44hd2ZiaIXtZY4hSy1|Mz3BJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{42QCCwTR?= MVXTRW5ITVJ?
PC-3 cell M2TPemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWDIcVluUW6qaXLpeIlwdiCxZjDoeY1idiCSQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45QSCwTR?= M{TM[XNCVkeHUh?=
COLO-684 cell NXjobmxUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{TCXmlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22PFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06NjJzIH7N NH;N[5NUSU6JRWK=
SNU-387 cell NIj0T2JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1H4fWlvcGmkaYTpc44hd2ZiaIXtZY4hW06XLUO4O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvPDlibl2= NXHhfHVRW0GQR1XS
U251 cell NGTZbVFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4TkUGlvcGmkaYTpc44hd2ZiaIXtZY4hXTJ3MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmuPFYhdk1? MYTTRW5ITVJ?
A673 cell NVzQOoluT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFXOfVVKdmirYnn0bY9vKG:oIHj1cYFvKEF4N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU43KG6P NUfVNIlrW0GQR1XS
human T47D cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFHQTXFKdmirYnn0bY9vKG:oIHj1cYFvKFR2N1SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOk44QSCwTR?= NXmwd5B2W0GQR1XS
A549 cell M3HqOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zOT62JI5O MWjTRW5ITVJ?
PC-14 cell M3nwXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUPQTmtkUW6qaXLpeIlwdiCxZjDoeY1idiCSQz2xOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI1Njd|IH7N NUC3[|B1W0GQR1XS
A704 cell M{HET2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWDJcohq[mm2aX;uJI9nKGi3bXHuJGE4ODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Nz60OUBvVQ>? Ml7CV2FPT0WU
MCF7 cell NEPRTZJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mlz6TY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{GuN|Yhdk1? M1\5WHNCVkeHUh?=
PC3 cells MV;GeY5kfGmxbjDhd5NigQ>? NU\KNm9CUW6qaXLpeIlwdiCxZjDQSGsyNW2nZHnheIVlKEGNVDDwbI9{eGixconsZZRqd25iYYSgWIhzOzB6IILld4llfWViaX6gbJVu[W5iUFOzJINmdGy|IHL5JGVNUVODLDDJR|UxRTBwMUGzJO69VQ>? MoruNlE{PDF4N{W=
F-36P cells MkO0VJJwdGmoZYLheIlwdiCjc4PhfS=> M3e5UGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRj2zOnAh[2WubIOsJGlEPTB;MD6yPEDPxE1? NVLPXJRzOjF|NEG2O|U>
OCI-AML2 cells MnLPVJJwdGmoZYLheIlwdiCjc4PhfS=> MXjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE:FST3BUWwzKGOnbHzzMEBKSzVyPUCuN|Uh|ryP NEHGc3MzOTN2MU[3OS=>
K562 cells NH7hRnVRem:uaX\ldoF1cW:wIHHzd4F6 NUjxNpRJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzMEBKSzVyPUG4JO69VQ>? NYnMOXZuOjF|NEG2O|U>

... Click to View More Cell Line Experimental Data

In vivo Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: Hs294T, HSB2, and Ramos
  • Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • Incubation Time: 18, or 24 hours
  • Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~100 mg/kg
  • Administration: Intravenous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 80 mg/mL (199.75 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
1% DMSO+30% polyethylene glycol+1% Tween 80
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 400.5
Formula

C19H20N4O2S2

CAS No. 488832-69-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01280786 Unknown status Acute Myeloid Leukemia Synta Pharmaceuticals Corp. January 2011 Phase 1
NCT00888615 Unknown status Malignant Ovarian Mixed Epithelial Tumor|Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Ovarian Carcinoma Gynecologic Oncology Group|National Cancer Institute (NCI) December 2010 Phase 2
NCT00827203 Suspended Metastatic Solid Tumors Synta Pharmaceuticals Corp. January 2009 Phase 1
NCT00808418 Completed Prostate Cancer Synta Pharmaceuticals Corp. November 2008 Phase 1
NCT00522834 Terminated Melanoma Synta Pharmaceuticals Corp. August 2007 Phase 3
NCT00087997 Completed Soft Tissue Sarcoma Synta Pharmaceuticals Corp. July 2004 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

Tags: buy Elesclomol (STA-4783) | Elesclomol (STA-4783) supplier | purchase Elesclomol (STA-4783) | Elesclomol (STA-4783) cost | Elesclomol (STA-4783) manufacturer | order Elesclomol (STA-4783) | Elesclomol (STA-4783) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID